Browsing Tag
neuroscience
9 posts
Alkermes raises Avadel bid to $2.37bn with enhanced CVR terms tied to LUMRYZ FDA milestone
Alkermes raises Avadel bid to $2.37B with improved CVR linked to FDA approval for LUMRYZ in idiopathic hypersomnia. Read the full transaction breakdown.
Vyepti and Rexulti power Lundbeck (CPH: LUN) to raise 2025 guidance after 22% adjusted EBITDA surge
Lundbeck lifts 2025 guidance as Vyepti and Rexulti drive 22% EBITDA growth. Explore the neuroscience-focused strategy powering its latest earnings surge.
AbbVie completes $1.2bn acquisition of Gilgamesh’s bretisilocin: Is big pharma finally embracing psychedelic psychiatry?
AbbVie completes $1.2B acquisition of bretisilocin from Gilgamesh, betting big on short-acting psychiatric drugs. Here’s what the deal signals for depression care.
Johnson & Johnson’s $55bn bet: What it means for healthcare and investors
Johnson & Johnson is investing $55 billion in U.S. manufacturing, R&D, and technology, reinforcing its leadership in pharmaceuticals. Find out more.
AbbVie reports 2024 financial results: Revenue growth driven by immunology and neuroscience
AbbVie (NYSE: ABBV) has released its full-year and fourth-quarter 2024 financial results, showing continued revenue growth despite challenges…
Jazz Pharmaceuticals to acquire GW Pharmaceuticals in $7.2bn deal
In a significant move within the pharmaceutical industry, Irish biopharma company Jazz Pharmaceuticals has announced an agreement to…
Takeda’s $62bn acquisition of Shire: A game-changing move for global pharma
In a landmark deal, Takeda Pharmaceutical Company has successfully completed its previously announced acquisition of Shire, an Irish…
Novartis to acquire AveXis for $8.7bn to expand gene therapy and neuroscience portfolio
Novartis, a Swiss pharmaceutical giant, has confirmed a substantial acquisition of AveXis, a US-based gene therapy company, for…
Biogen strikes $600m deal with Pfizer for promising schizophrenia drug
Biogen, a leading US biotechnology firm, has reached a significant agreement to acquire Pfizer’s neurology drug candidate, PF-04958242,…